GE Healthcare patents advance diagnostic imaging across multiple technologies
GE Healthcare and its affiliated entities have filed a broad range of patents in diagnostic imaging, covering molecular imaging agents, patient positioning systems, ultrasound technologies, contrast media, and optical imaging. These filings reflect continued investment in improving image quality, patient safety, and targeted diagnostics.
In molecular imaging, several patents focus on matrix metalloproteinase inhibitors designed for in vivo imaging. These compounds are labeled with gamma-emitting radionuclides and used in single photon emission computed tomography to detect cardiovascular and inflammatory diseases. A granted patent in this area outlines both the imaging agents and preparation kits for clinical use.
The company has also developed systems to improve patient positioning in emission tomography. A recent patent application describes a method that aligns the region of interest within the scanner’s axial field of view, increasing detection sensitivity and enhancing image accuracy compared with standard anatomical references.
Ultrasound imaging remains another major area of innovation. GE Healthcare has patented diagnostic and therapeutic agents based on gas-filled microbubbles stabilized by surfactant layers. These agents can be linked to targeting molecules, enabling precise imaging and therapy. Additional granted patents cover formulations that combine targeting vectors with gas-containing agents to improve signal detection and treatment delivery.
In X-ray imaging, the company has focused on contrast media designed to reduce iodine concentration while maintaining diagnostic performance. These formulations aim to lower patient exposure to radiation and improve safety. Related patents describe imaging methods that combine low-iodine agents with advanced reconstruction techniques to reduce image noise. Other filings detail iodine-based compounds that enhance contrast between different tissues.
GE Healthcare has also explored optical imaging technologies. Patents in this field describe the use of biocompatible particulate materials as contrast agents for in vivo light imaging, enabling the generation of spatial and temporal images of biological structures.
Together, these patents demonstrate a diversified strategy that spans hardware systems, imaging agents, and computational methods, supporting advancements across major diagnostic imaging modalities.
-
17:15
-
17:00
-
16:45
-
16:30
-
16:15
-
16:00
-
15:45
-
15:30
-
15:15
-
15:00
-
14:52
-
14:45
-
14:30
-
14:06
-
13:10
-
12:55
-
12:40
-
12:25
-
12:10
-
11:55
-
11:40
-
11:35
-
11:32
-
11:20
-
11:17
-
11:17
-
11:12
-
11:08
-
11:07
-
11:07
-
11:05
-
10:57
-
10:56
-
10:56
-
10:56
-
10:50
-
10:35
-
10:20
-
10:05
-
09:50
-
09:35
-
09:20
-
09:05
-
08:55
-
08:40
-
07:25
